{rfName}
Ef

Indexed in

License and Use

Icono OpenAccess

Citations

12

Altmetrics

Analysis of institutional authors

Villamañán, ElenaAuthorQuirce, SantiagoAuthorAlvarez-Sala, RodolfoAuthor

Share

February 3, 2025
Publications
>
Review
Sí

Efficacy Assessment of Biological Treatments in Severe Asthma

Publicated to: Journal Of Clinical Medicine. 14 (2): 321- - 2025-01-01 14(2), DOI: 10.3390/jcm14020321

Authors:

Laorden, D; Domínguez-Ortega, J; Romero, D; Villamañán, E; Mariscal-Aguilar, P; Granda, P; Quirce, S; alvarez-Sala, R; ASMAGRAVE HULP Grp
[+]

Affiliations

CIBER Resp Dis, Madrid 28046, Spain - Author
Gomez Ulla Mil Hosp, Pharm Dept, Madrid 28047, Spain - Author
Hosp La Paz, IdiPAZ, Dept Allergy, Madrid 28046, Spain - Author
Hosp La Paz, IdiPAZ, Dept Pharm, Madrid 28029, Spain - Author
Univ Autonoma Madrid, Hosp La Paz, Dept Pneumol, IdiPAZ, Madrid 28046, Spain - Author
See more

Abstract

Uncontrolled, severe asthma remains a significant clinical challenge, affecting a small proportion of asthma patients worldwide. Despite advancements in treatment options, a subset of patients continues to experience frequent exacerbations, uncontrolled symptoms, and impaired quality of life. The advent of biological therapies has revolutionized the management of severe asthma, offering targeted treatments that address specific inflammatory pathways. This review provides a comprehensive overview of the efficacy and response criteria of biological treatments in severe asthma, focusing on clinical, functional, and inflammatory markers used to help in the evaluation of the biologic treatment. Key response criteria include symptom control, reduction in exacerbations, improvement in lung function, and a reduction in or the discontinuation of oral corticosteroids. Biomarkers such as blood eosinophils and exhaled nitric oxide (FeNO) are essential tools in guiding treatment adjustments. Real-world studies underscore the importance of personalized treatment strategies, as variability in response to biological therapies can be significant. The emergence of tools such as the FEOS score and EXACTO questionnaire offer quantitative measures for assessing biological response and guiding clinical decisions. Additionally, predictive factors for better or poorer responses, such as pre-treatment lung function and comorbidities, like obesity and rhinosinusitis, are critical in patient selection. This review highlights the need for ongoing reassessments and potential modifications of therapy in cases of suboptimal response. Practical considerations for switching biological therapies are discussed, emphasizing the importance of tailoring treatments to individual patient profiles and disease phenotypes. With the continued development of personalized medicine, the outlook for patients with severe asthma is improving, selecting specific biomarkers to improve the selection of the biologic treatment.
[+]

Keywords

BiologicBiomarkersEfficacy toolsMepolizumabPersonalized medicinPersonalized medicineReal-lifeSafetSevere asthmaSevere eosinophilic asthma

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal of Clinical Medicine due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2025, it was in position 65/332, thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine, General & Internal.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-05:

  • WoS: 4
  • Scopus: 4
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-05:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 14 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

    It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

    • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
    [+]

    Leadership analysis of institutional authors

    There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Laorden, Daniel) and Last Author (ALVAREZ-SALA WALTHER, RODOLFO).

    the author responsible for correspondence tasks has been Laorden, Daniel.

    [+]